gene_symbol
CD19
hgnc_id
HGNC:1633
binding_type
antigen recognition
cytotoxicity
YES
cytotoxicity_type
DIRECT
cytotoxicity_mechanism
Inebilizumab binds CD19 on B-lineage cells and triggers Fc-mediated effector functions—enhanced ADCC by NK cells/macrophages and complement-dependent cytotoxicity (and phagocytosis)—leading to depletion of CD19+ cells.
enzyme_product
Off
epitope
Off
variant
Off
isoform
Off
hla_specific
Off
gated
Off
other_modifier
B-cell surface glycoprotein expressed from pro-B to early plasma cell stages
trial_id_tar_ref
drug_id_tar_ref
disease_id_tar_ref
nct_id_tar_ref
NCT05891379
disease_id_num_tar_ref
2081
drug_id_num_tar_ref
5562